[Edaily Reporter NA EUN-KYUNG ] NeoImmuneTech, Inc.(950220)is establishing a direct sales system in the U.S. for “Endari,” a treatment for sickle cell disease, and expanding its pharmaceutical sales revenue. Since launching direct sales last May, the company has recorded net sales of 4.1 billion won in the U.S. through the third quarter of this year.
NeoImmuneTech, Inc. announced on the 17th that it has established a business structure to directly handle Endari’s U.S. sales, product supply, and sales revenue management. While continuing sales efforts targeting medical institutions and specialty pharmacies with its existing sales force, the company has also built a distribution network through local pharmaceutical wholesalers.
Endari is an oral powder medication used to reduce the occurrence of acute complications in patients with sickle cell disease. Taken twice daily, it was approved by the U.S. Food and Drug Administration (FDA) in 2017.
During the transition to direct sales in the U.S., NeoImmuneTech, Inc. recruited three field managers who had previously been responsible for sales of existing products. Together, they have over 47 years of combined experience, having managed new drug launches and sales at global pharmaceutical companies such as Merck, Bayer, and Daiichi Sankyo.
According to the company, it is supporting the continued prescribing of the drug for patients while maintaining business relationships with existing healthcare providers and specialty pharmacies. The local sales organization is responsible for providing product information to healthcare providers and collaborating with patient advocacy groups, and is also expanding outreach activities for Spanish-speaking patients. Negotiations with insurance companies are being handled by a market access specialist who previously managed the commercialization of Endari in the U.S.
Product distribution is carried out through major U.S. pharmaceutical wholesalers such as McKesson, Senkora, and Cardinal Health. NeoImmuneTech, Inc. obtained a pharmaceutical wholesale license in Maryland last May and is currently preparing to transition contracts using its National Drug Code (NDC).
NeoImmuneTech, Inc. directly recognizes revenue from U.S. sales. Under this structure, the company determines selling prices and inventory management policies and manages accounts receivable. To this end, it has hired two full-time professionals who hold U.S. pharmacist licenses. The company collaborates with external specialized firms for logistics, rebate settlements, and pharmacovigilance.
The direct sales business is already reflected in this year’s financial results. According to the quarterly report submitted on the 11th, NeoImmuneTech, Inc.’s cumulative revenue from January through September this year was 6.56354 billion won. Of this, net sales of Endari in the U.S. amounted to approximately 4.1 billion won, accounting for 62% of the total.
The third quarter of this year marks the first quarter in which the full three months of sales performance since the launch of direct sales have been reflected. Full-quarter sales performance is also expected to be reflected in the fourth quarter. During the same period, NeoImmuneTech, Inc.’s operating loss was 14.5 billion won, a 24% decrease compared to the same period last year.
The company plans to use the revenue from Endari sales to fund business operations and research and development. Based on current development plans, the company believes it can continue operations without additional funding and plans to secure any future necessary funds through pharmaceutical sales, technology transfer revenue, and external research grants.
Kim Tae-kyung, CEO of NeoImmuneTech, Inc., stated, “Even after switching to direct sales, we have maintained our relationships with existing healthcare providers, specialty pharmacies, and patient groups, ensuring that repeat prescriptions continue, and sales have been generated every month since May.” He added, “We will expand prescriptions to new patient demographics, such as Spanish-speaking patients, and new sales regions to increase revenue based on repeat prescriptions.”
SK hynix has developed a 122-terabyte (TB) ultra-high-capacity solid-state drive (SSD) for use in artificial intelligence (AI) data centers and has begun supplying samples to customers. Amid growing d…
#SANIGEN Co., Ltd., a molecular diagnostics company specializing in microorganisms, has filed a patent for proprietary technology capable of detecting the dengue virus in just one hour, marking the of…
With the U.S. government introducing export control regulations that block Chinese companies from accessing overseas data centers via workarounds, changes are expected in the global competition to att…